It’s still early days for 2 coronavirus vaccine candidates, but trial results published yesterday in The Lancet earned promising (though qualified) results.
The first vaccine, developed by Oxford University and AstraZeneca and sporting the catchy name of ChAdOx1 nCoV-19, safely generated strong immune responses in a trial involving 1,000+ patients, according to a Lancet article reported on by The Washington Post.
Larger phase 3 trials of the vaccine are already underway in the UK, Brazil, and South Africa with results expected sometime this fall, STAT reports.